Persistent Systems has announced a collaboration with NVIDIA to accelerate AI-powered solutions for the healthcare and life sciences (HLS) sector, including the launch of its Generative Molecules and Virtual Screening (GenMolVS) solution.
The partnership aims to enhance computational drug discovery by leveraging generative AI and advanced analytics, enabling faster and more efficient research outcomes.
Persistent will utilize the NVIDIA AI Enterprise platform for specialized life sciences applications, including preclinical research, allowing high-fidelity molecular simulations and large-scale virtual screening. This approach helps model biological and chemical behavior digitally before real-world lab testing.
The GenMolVS solution, built on NVIDIA BioNeMo and NeMo Agent Toolkit, uses AI-driven simulations and intelligent agents to streamline drug discovery workflows, from virtual screening and candidate prioritization to experimental planning. This enables research teams to accelerate early-stage discovery, reduce risks, and improve clinical success rates.
Persistent also plans to leverage NVIDIA’s Nemotron models, accelerated computing infrastructure, and AI microservices to deploy scalable, production-grade applications with real-time decision-making capabilities.
The collaboration will further strengthen Persistent’s AI and LLM engineering capabilities through access to NVIDIA’s infrastructure, training, and certification programs, supporting the development of advanced data and AI platforms for clients.
Company executives said the initiative will help biopharma firms transition from lengthy experimental cycles to faster, AI-led discovery processes, improving efficiency without compromising scientific rigor.